Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
NCT03520686Phase 3Terminated
- Sponsor
- ImmunityBio, Inc.
- Start
- May 2018
- Primary completion
- Oct 2025
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of nogapendekin alfa inbakicept in non-small cell lung cancer (NSCLC), sponsored by ImmunityBio, Inc.. Started May 2018; status: terminated.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03520686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03520686.